Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection
The aim of this study was to investigate the treatment response of entecavir (ETV) in children and adolescents with chronic hepatitis B (CHB) who acquired infection perinatally or during early childhood. Methods: A total of nine treatment-naïve patients [median aged 12.2 years (range: 2.6–18.0); fiv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-10-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957215001849 |
| _version_ | 1818671020889866240 |
|---|---|
| author | Kai-Chi Chang Jia-Feng Wu Hong-Yuan Hsu Huey-Ling Chen Yen-Hsuan Ni Mei-Hwei Chang |
| author_facet | Kai-Chi Chang Jia-Feng Wu Hong-Yuan Hsu Huey-Ling Chen Yen-Hsuan Ni Mei-Hwei Chang |
| author_sort | Kai-Chi Chang |
| collection | DOAJ |
| description | The aim of this study was to investigate the treatment response of entecavir (ETV) in children and adolescents with chronic hepatitis B (CHB) who acquired infection perinatally or during early childhood.
Methods: A total of nine treatment-naïve patients [median aged 12.2 years (range: 2.6–18.0); five girls and four boys], with hepatitis B e antigen (HBeAg) seropositive > 6 months, alanine aminotransferase (ALT) > 2 times of upper limit of normal value (30 IU/L), were enrolled for ETV therapy. They received ETV therapy with a dose of 0.015 mg/kg/d, with a maximal dose of 0.5 mg daily for at least 52 weeks. Another 27 untreated CHB patients matched for age, sex, ALT levels, and HBeAg status were recruited as the control group. A complete response at 48–52 weeks was defined as follows: (1) normalization of ALT; (2) undetectable hepatitis B virus DNA; and (3) HBeAg/anti-HBe seroconversion. All 36 patients were retrospectively reviewed for their biochemical, serological, and virologic responses.
Results: ETV-treated patients achieved rapid ALT normalization (all before 8 months of treatment) compared with the control group (p < 0.001) and they had a greater chance of achieving undetectable HBV DNA levels at Week 52 after treatment (55.6% vs. 11.1%, p = 0.013). The cumulative incidence rates of HBeAg seroconversion were similarly high in both groups (ETV group 44% at 1 year 78% at 2 years; control group 37% at 1 year 63% at 2 years, respectively). The ETV group also had a trend of better complete response than the control group (22.2% vs. 0%, p = 0.057). None of the ETV-treated patients reported significant adverse effects.
Conclusion: Entecavir for pediatric CHB treatment is safe and shows clinical benefits in short-term biochemical and virologic responses. Further studies to determine long-term remission and drug resistance are required. |
| first_indexed | 2024-12-17T07:17:22Z |
| format | Article |
| id | doaj.art-764ab866cb4a4392bb59b82a474fc860 |
| institution | Directory Open Access Journal |
| issn | 1875-9572 |
| language | English |
| last_indexed | 2024-12-17T07:17:22Z |
| publishDate | 2016-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj.art-764ab866cb4a4392bb59b82a474fc8602022-12-21T21:58:51ZengElsevierPediatrics and Neonatology1875-95722016-10-0157539039510.1016/j.pedneo.2015.09.009Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus InfectionKai-Chi Chang0Jia-Feng Wu1Hong-Yuan Hsu2Huey-Ling Chen3Yen-Hsuan Ni4Mei-Hwei Chang5Department of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanThe aim of this study was to investigate the treatment response of entecavir (ETV) in children and adolescents with chronic hepatitis B (CHB) who acquired infection perinatally or during early childhood. Methods: A total of nine treatment-naïve patients [median aged 12.2 years (range: 2.6–18.0); five girls and four boys], with hepatitis B e antigen (HBeAg) seropositive > 6 months, alanine aminotransferase (ALT) > 2 times of upper limit of normal value (30 IU/L), were enrolled for ETV therapy. They received ETV therapy with a dose of 0.015 mg/kg/d, with a maximal dose of 0.5 mg daily for at least 52 weeks. Another 27 untreated CHB patients matched for age, sex, ALT levels, and HBeAg status were recruited as the control group. A complete response at 48–52 weeks was defined as follows: (1) normalization of ALT; (2) undetectable hepatitis B virus DNA; and (3) HBeAg/anti-HBe seroconversion. All 36 patients were retrospectively reviewed for their biochemical, serological, and virologic responses. Results: ETV-treated patients achieved rapid ALT normalization (all before 8 months of treatment) compared with the control group (p < 0.001) and they had a greater chance of achieving undetectable HBV DNA levels at Week 52 after treatment (55.6% vs. 11.1%, p = 0.013). The cumulative incidence rates of HBeAg seroconversion were similarly high in both groups (ETV group 44% at 1 year 78% at 2 years; control group 37% at 1 year 63% at 2 years, respectively). The ETV group also had a trend of better complete response than the control group (22.2% vs. 0%, p = 0.057). None of the ETV-treated patients reported significant adverse effects. Conclusion: Entecavir for pediatric CHB treatment is safe and shows clinical benefits in short-term biochemical and virologic responses. Further studies to determine long-term remission and drug resistance are required.http://www.sciencedirect.com/science/article/pii/S1875957215001849chronic hepatitis Bentecavir |
| spellingShingle | Kai-Chi Chang Jia-Feng Wu Hong-Yuan Hsu Huey-Ling Chen Yen-Hsuan Ni Mei-Hwei Chang Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection Pediatrics and Neonatology chronic hepatitis B entecavir |
| title | Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection |
| title_full | Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection |
| title_fullStr | Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection |
| title_full_unstemmed | Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection |
| title_short | Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection |
| title_sort | entecavir treatment in children and adolescents with chronic hepatitis b virus infection |
| topic | chronic hepatitis B entecavir |
| url | http://www.sciencedirect.com/science/article/pii/S1875957215001849 |
| work_keys_str_mv | AT kaichichang entecavirtreatmentinchildrenandadolescentswithchronichepatitisbvirusinfection AT jiafengwu entecavirtreatmentinchildrenandadolescentswithchronichepatitisbvirusinfection AT hongyuanhsu entecavirtreatmentinchildrenandadolescentswithchronichepatitisbvirusinfection AT hueylingchen entecavirtreatmentinchildrenandadolescentswithchronichepatitisbvirusinfection AT yenhsuanni entecavirtreatmentinchildrenandadolescentswithchronichepatitisbvirusinfection AT meihweichang entecavirtreatmentinchildrenandadolescentswithchronichepatitisbvirusinfection |